Table 1.

Table showing the information of majorly used antiviral drugs with the information of primary indication, secondary indication, inhibition efficiency` and references

Repurposed drugs	Primary indication	Repurposed indication	Inhibition efficacy	References
Ribavirin	HCV	CHIKV	EC50 = 2.5 ± 0.3 μM	[23]
		CCHV	IC50 = 0.04 ± 0.01 mM	[24]
		DENV	EC50 = 7.7 ± 0.6 μM	[25]
		EBV	EC50 = 60.1 μM	[26]
		MERS	EC50 = 9.99 ± 2.97 μM	[27]
		SARS-CoV-2	EC50 = 26.739 μg/ml	[28]
		SARS	EC50= >100 μM	[29]
		ZIKV	EC50 = 12 ± 6.6 μM	[30]
Chloroquine	Malaria	SARS-CoV-2	EC50 = 5.47 μM	[31]
		SARS	EC50 = 3.3 μM	[32]
		MERS	EC50 = 3.0 μM	[32]
		EBV	EC50 = 16 μM	[33]
		CHIKV	EC50 = 10 ± 5 μM	[34]
Favipiravir	IFV	ZIKV	EC50 = 22 ± 15 μM	[30]
		RVFV	EC50 = 5 μg/ml	[35]
		SARS-CoV-2	EC50 = 61.88 μM	[36]
		NiV	EC50 = 14.57 μM	[37]
Mycophenolic Acid	Organ rejection (immunosuppressants)	SARS-CoV-2	IC50 = 20 nM	[38]
		WNV	IC50= > 100 μg/ml	[39]
		MERS	EC50 = 0.17 ± 0.03 μM	[40]
		EBV	IC50 = 0.96 μg/ml	[41]
		LASV	IC50 = 0.34 μg/ml	[41]
Nitazoxanide	Diarrhea	IFV	EC50 = 1 μM	[42]
		ZIKV	Log Reduction= > 100 fold	[43]
		SARS-CoV-2	EC50 = 2.12 μM	[44]
		MERS	IC50 = 0.92 μg/ml	[45]
		CHIKV	EC50 = 3.01 ± 0.61 μM	[46]
Amodiaquine	Malaria	SARS-CoV-2	EC50 = 1832.7 mg/ml	[28]
		ZIKV	EC50 = 3.07 ± 0.36 μM	[47]
		MARV	IC50 = 2.3 μM	[48]
		DENV	EC50 = 7.41 ± 1.09 μM	[49]